Order results by:
| Issue | Title | |
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... is an empirical assessment of the cost-effectiveness threshold that reflects the utmost productivity of the health ..." | ||
| Vol 5, No 1 (2012) | PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION | Abstract similar documents |
| R. Yagudina, A. Kulikov, B. Misikova | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... .). Cost-effectiveness analysis was performed. Results: The developed model allows to assess the risk ..." | ||
| Vol 8, No 2 (2015) | CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA | Abstract similar documents |
| Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova | ||
| "... . For the pharmacoeconomic analysis we used the cost-effectiveness ratio. Results. Our analysis showed that the scheme ..." | ||
| Vol 9, No 3 (2016) | METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... included 2259 patient’s data files. The age of patients ranged from 0 to 18 years old. «Cost-effectiveness ..." | ||
| Vol 10, No 2 (2017) | ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) | Abstract similar documents |
| Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina | ||
| "... approved for national clinical practice. Aim. To perform a cost-effectiveness analysis of the commonly ..." | ||
| Vol 10, No 4 (2017) | PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... and social care were evaluated for the treatment of hemophilia A and its complication; a cost-effectiveness ..." | ||
| Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
| I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
| "... & Lawrence classification. We calculated the cost-effectiveness from the direct costs and treatment ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| "... . The cost-effectiveness ratios for omalizumab, mepolizumab and reslizumab were calculated and compared ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... Objective: to perform cost-effectiveness analysis of the treatment for adult patients ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer | Abstract similar documents |
| Yu. Yu. Petukhova, E. V. Eliseeva, M. V. Volkov, O. N. Li, A. G. Petukhova | ||
| "... with this disease. Material and methods. The authors performed a comparative cost-effectiveness analysis ..." | ||
| Vol 18, No 2 (2025) | Clinical and economic evaluation of antibacterial therapy for nosocomial pneumonia on the example of a multidisciplinary hospital in Moscow | Abstract similar documents |
| D. D. Ivanova, I. N. Sychev, N. B. Lazareva | ||
| "... pathogens were selected for analysis. Direct medical costs and cost-effectiveness coefficients were ..." | ||
| Vol 18, No 3 (2025) | Cost and clinical effectiveness of fixed-dose combination therapies in the treatment of glaucoma patients: a systematic review | Abstract similar documents |
| Sh. Z. Umarova, Z. R. Usmonova, N. M. Normatova, N. M. Sultanbayeva | ||
| "... effectiveness, as well as cost-effectiveness and cost-utility ratios. Results. TT-FCD proved to be more cost ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... . Инкрементальный показатель «затраты–эффективность» (англ. incremental cost-effectiveness ratio, ICER) на 1 год ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... анализ «затраты – эффективность» (англ. cost-effectiveness analysis, CEA) использования ланреотида или ..." | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... -to-pay threshold (WTP), the threshold value of the incremental cost-effectiveness ratio (ICeR), in europe ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... Introduction. Presently, the willingness-to-pay threshold (cost-effectiveness threshold ..." | ||
| Vol 5, No 2 (2012) | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS | Abstract similar documents |
| A. V. Rudakova | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
| A. U. Kulikov | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
| R. I. Yagudina, M. M. Murashko | ||
| "... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... radio iodine refractory differentiated thyroid cancer in the Russian Federation. Methods. Cost ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... impact and the “cost-effectiveness” parameters were analyzed using the MS Excel-model based on a 3-year ..." | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... to perform the cost-effectiveness analysis, incremental analysis, and «budget impact» analysis. Results ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... ’ medical records. The cost-effectiveness analysis, incremental analysis, and «budget impact» analysis were ..." | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
| A. G. Tolkushin, N. L. Pogudina | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... . The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost ..." | ||
| Vol 15, No 3 (2022) | Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis | Abstract similar documents |
| А. V. Kukurika | ||
| "... Objective: to systematize data on cost-effectiveness evaluation of new multidrug and extensively ..." | ||
| Vol 13, No 2 (2020) | Affordability of in vivo gene therapy. Problems and potential solutions | Abstract similar documents |
| V. V. Omelyanovskiy, N. Z. Musina, V. A. Lemeshko, A. A. Antonov, F. V. Gorkavenko | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy | Abstract similar documents |
| I. N. Dyakov, S. R. Varfolomeеva | ||
| "... data. The methods of pharmacoeconomic analysis included a clinical-economic analysis (cost ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| "... g/l was 13,097 rubles for Monofer and 15,681 rubles for Ferinject®. The values of the cost-effectiveness ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... показатель «затраты–эффективность» (англ. incremental cost-effectiveness ratio, ICER) за 1 QALY в основном ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract similar documents |
| O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
| "... of combined treatment is the least expensive in the morphine sulfate group (incremental cost-effectiveness ..." | ||
| Vol 14, No 3 (2021) | An economic evaluation of pre-dialysis stage of chronic kidney disease | Abstract similar documents |
| E. I. Rumiantseva, M. V. Avxentyeva | ||
| "... для поиска: ‘chronic kidney disease (CKD)’, ‘cost-effectiveness’, ‘economic evaluation’, ‘economic ..." | ||
| Vol 16, No 3 (2023) | Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib ..." | ||
| Vol 16, No 4 (2023) | Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis C | Abstract similar documents |
| I. A. Narkevich, E. A. Tsitlionok | ||
| "... эффективности терапии проводилась с помощью расчета коэффициента «затраты–эффективность» (англ. cost ..." | ||
| Vol 18, No 4 (2025) | Clinical and economic assessment of an extended release lanreotide formulation (Somatuline® Autogel®) in patients with gastrointestinal neuroendocrine tumors | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin, Yu. A. Kolosov, L. B. Vaskova | ||
| "... – эффективность» (англ. cost-effectiveness ratio, CER) и инкрементального коэффициента «затраты – эффективность ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation | Abstract similar documents |
| A. Yu. Kulikov, L. A. Komarov | ||
| "... of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| Vol 11, No 4 (2018) | Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach | Abstract similar documents |
| A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya | ||
| "... analysis and a comparison of costs and effectiveness (cost-effectiveness). The effectiveness analysis ..." | ||
| Vol 14, No 2 (2021) | Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation | Abstract similar documents |
| D. G. Shchurov, V. S. Dombrovskiy | ||
| "... ; incremental cost-effectiveness ratio (ICER); changes in the amount of total direct medical costs; resizing ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... «затраты–эффективность» (англ. incremental cost-effectiveness ratio, ICER) – 24 530,20 и 21 526,50 руб ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... . The cost-effectiveness of tixagevimab and cilgavimab was evaluated in persons ≥18 years old not vaccinated ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... . Objective: to evaluate the clinical and cost-effectiveness of using ATZ and Durv as first-line therapy ..." | ||
| Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| Online First | Clinical and economic aspects of semaglutide use in the treatment of obesity | Abstract similar documents |
| A. L. Tibilova, D. D. Kozaeva, R. R. Aslakhanova, V. Z. Tedety, M. Z. Tazurkaeva, D. E. Gurtsieva, E. E. Kanteeva, M. S. Gabueva, V. I. Guatsaeva, A. M. Dzhigkaeva, A. A. Tsokova, A. S. Petukhova | ||
| "... loss”, “efficacy”, “safety”, “cost-effectiveness”, “health economics”, а также «семаглутид», «агонисты ..." | ||
| Vol 1, No 19 (2026) | Pharmacoeconomic evaluation of contemporary treatment, prevention, and screening strategies for melanoma: a review of evidence and implications for the Russian healthcare system | Abstract similar documents |
| V. M. Polezhaeva, D. S. Beloglazova, E. S. Trunina, A. A. Grinina, A. M. Burmagina, D. N. Gamzova, Yu. M. Kirdyashkina, А. N. Novikov, A. A. Khudiyarov, L. Aydasheva, D. F. Vorobyev, D. R. Khayrutdinova | ||
| "... for assessing the cost-effectiveness of pharmacotherapy using real-world data (RWD), to summarize international ..." | ||
| Vol 6, No 2 (2013) | COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... . We performed cost-effectiveness analysis on the basis of two tyrosine kinase inhibitors in Russian Federation ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment | Abstract similar documents |
| A. U. Kulikov, V. V. Babiy | ||
| "... research compared the cost-effectiveness and the budget impact results of using Contour TS, Accu-Chek ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... приращения эффективности затрат (incremental cost-effectiveness ratio, ICER) на один сохраненный год жизни ..." | ||
| 1 - 50 of 56 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
